Oct 24 (Reuters) - Johnson & Johnson on Saturday said its experimental once-daily oral prostate cancer drug caused tumors to ...

UChicago researchers identify a previously unknown RNA molecule that allows prostate cancer cells to escape targeted ...

An international phase 3 clinical trial that treated patients with high-risk localized and locally advanced prostate cancer ...

Researchers investigating a deadly cancer’s ability to evade treatment have discovered its secret weakness, paving the way ...

Scientists have discovered vital clues to help predict, more than a decade in advance, which men may develop prostate cancer.

A WARRINGTON man whose advanced prostate cancer was only discovered after he mistook it for a training injury has had his ...

Proud to Contribute Alongside Andrew Armstrong to New Research in Advanced Prostate Cancer / Abstract 2216O, Andrew Armstrong ...

A new alpha-emitting radiopharmaceutical therapy (RPT) for advanced prostate cancer was well tolerated, with no dose-limiting ...

Johnson & Johnson (NYSE:JNJ) has presented Phase 1 clinical trial results for JNJ-6143, an investigational oral treatment for advanced prostate cancer, at the European Society for Medical Oncology ...

Perioperative apalutamide plus ADT and surgery lowered risk of recurrence or death by 62% in high-risk localized or locally advanced prostate cancer.

A study by Leicester researchers shows that the timing of radiotherapy treatment may be as important as how it is given for ...